GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery, Published online: 25 April 2025; doi:10.1038/s41573-025-01183-8 GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based medicines, focusing on novel GLP-1 receptor agonists and GLP-1-based multi-agonists. Considerations and challenges in the development of GLP-1-based therapies and potential future indications are […]
GLP-1 drugs are proving immune from prescription skepticism
While some Americans might feel doubtful about prescriptions, others are doing all they can to acquire GLP-1 drugs. Carly Johnson of Momentum Worldwide says the results of a new survey show just how popular they are. If you spend even a little bit of time online, you’ve probably seen the social discourse around prescription medications […]
Journal Paper – “Adipose tissue retains an epigenetic memory of obesity after weight loss”
Hinte LC, Castellano-Castillo D, Ghosh A, Melrose K, Gasser E, Noé F, Massier L, Dong H, Sun W, Hoffmann A, Wolfrum C, Rydén M, Mejhert N, Blüher M, von Meyenn F. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 2024 Dec;636(8042):457-465. doi: 10.1038/s41586-024-08165-7. Epub 2024 Nov 18. PMID: 39558077; PMCID: PMC11634781. […]
GLP-1 RAs in Eating Disorders: Promising or Perilous?
Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge eating disorder? And how can clinicians protect patients from risk? Medscape Medical News
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
BACKGROUND Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide […]
GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder
Experts Recommend Medication for Pediatric MASLD Management
A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD. Medscape Medical News
Truth behind ‘Ozempic feet’ and grim side effects of dramatic weight loss
GLP-1 medications have been going viral for their transformative effects, but now people are raising concerns about a worrying new side-effect. Is it something to worry about or just a social media scare? We spoke with a doctor to find out
Should GLP-1 Receptor Agonists Be Recommended for Routine Use before Metabolic and Bariatric Surgery in Adolescents?
I congratulate Messiah et al on their publication entitled “Metabolic and Bariatric Surgery (MBS) Utilization in the Era of GLP-1 Receptor Agonists (GLP-1RA) among Adolescents Versus Adults.” The authors show an increase in adolescent MBS utilization from 2021-2023, which contrasts with adult data. This observation is interesting in the advent of second-generation GLP-1RAs (liraglutide and […]
Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]